AB Science Overview

  • Year Founded
  • 2001

Year Founded

  • Status
  • Public

  • Employees
  • 53

Employees

  • Stock Symbol
  • AB

Stock Symbol

  • Share Price
  • $1.17
  • (As of Friday Closing)

AB Science General Information

Description

AB Science is a France-based pharmaceutical company specialized in the research, discovery, development, and marketing of protein kinase inhibitors. It is engaged in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical factor in the field of cancer, chronic inflammatory diseases, neurological degenerative disorders and central nervous systems diseases in both human and veterinary medicine.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly Accelerator/Incubator backed
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Stock Exchange
PAR
Corporate Office
  • 3, Avenue George V
  • 75008 Paris
  • France
+33 01 00 00 00 00

AB Science Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AB Science Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.17 $1.17 $1.07 - $4.86 $60.9M 52.1M 134K -$0.22

AB Science Financials Summary

In Thousands,
USD
TTM 31-Dec-2023 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 200,385 200,385 363,247 621,587
Revenue 1,050 1,050 1,007 1,900
EBITDA (8,547) (8,547) (13,314) (13,491)
Net Income (10,873) (10,873) (14,315) (17,100)
Total Assets 28,187 28,187 25,567 24,083
Total Debt 21,114 21,114 25,691 9,456
Public Fundamental Data provided by Morningstar, Inc. disclaimer

AB Science Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore AB Science‘s full profile, request access.

Request a free trial

AB Science Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
AB Science is a France-based pharmaceutical company specialized in the research, discovery, development, and marketing o
Pharmaceuticals
Paris, France
53 As of 2023
00000
000000000 00000

000000

nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qu
0000000000000
Framingham, MA
0 As of 0000
000.00
000000000 000.00

0000 0

in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
0000 000000000
Cambridge, MA
000 As of 0000
00.000
000000000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

AB Science Competitors (84)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Xenetic Bioscience Corporation Framingham, MA 0 000.00 000000000 000.00
SAGE Therapeutics Formerly VC-backed Cambridge, MA 000 00.000 000000000 00.000
Blueprint Medicines Formerly VC-backed Cambridge, MA 000 00.000 000000000000 00.000
Harmony Biosciences Formerly VC-backed Plymouth Meeting, PA 000 00000 000000000000 00000
Seagen Formerly VC-backed Bothell, WA 0000 00.000 000000&0 00.000
You’re viewing 5 of 84 competitors. Get the full list »

AB Science Patents

AB Science Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4175639-A1 Masitinib for the treatment of castrate-resistant prostate cancer Active 17-May-2021 000000000
US-20230321081-A1 Masitinib for the treatment of castrate-resistant prostate cancer Pending 17-May-2021 0000000000
AU-2022276086-A1 Masitinib for the treatment of castrate-resistant prostate cancer Pending 17-May-2021 000000000
EP-4175639-B1 Masitinib for the treatment of castrate-resistant prostate cancer Active 17-May-2021 000000000
CA-3217490-A1 Masitinib for the treatment of castrate-resistant prostate cancer Pending 17-May-2021 A61K45/06
To view AB Science’s complete patent history, request access »

AB Science Executive Team (4)

Name Title Board Seat Contact Info
Alain Moussy Chief Executive Officer & Chairman
Laurent Guy Chief Financial Officer, Finance
Christian Fassotte Global Chief Medical Officer
You’re viewing 3 of 4 executive team members. Get the full list »

AB Science Board Members (3)

Name Representing Role Since
Alain Moussy AB Science Chief Executive Officer & Chairman 000 0000
Guillemette Latscha AB Science Board Member 000 0000
You’re viewing 2 of 3 board members. Get the full list »

AB Science Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AB Science Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore AB Science‘s full profile, request access.

Request a free trial

AB Science ESG

Risk Overview

Risk Rating

Updated February, 24, 2024

32.49 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 16,216

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 921

Rank

00.00

Percentile

Pharmaceuticals

Subindustry

00 of 452

Rank

00.00

Percentile

To view AB Science’s complete esg history, request access »

AB Science FAQs

  • When was AB Science founded?

    AB Science was founded in 2001.

  • Who is the founder of AB Science?

    Alain Moussy and Jean-Pierre Kinet MD are the founders of AB Science.

  • Who is the CEO of AB Science?

    Alain Moussy is the CEO of AB Science.

  • Where is AB Science headquartered?

    AB Science is headquartered in Paris, France.

  • What is the size of AB Science?

    AB Science has 53 total employees.

  • What industry is AB Science in?

    AB Science’s primary industry is Pharmaceuticals.

  • Is AB Science a private or public company?

    AB Science is a Public company.

  • What is AB Science’s stock symbol?

    The ticker symbol for AB Science is AB.

  • What is the current stock price of AB Science?

    As of 12-Jul-2024 the stock price of AB Science is $1.17.

  • What is the current market cap of AB Science?

    The current market capitalization of AB Science is $60.9M.

  • What is AB Science’s current revenue?

    The trailing twelve month revenue for AB Science is $1.05M.

  • Who are AB Science’s competitors?

    Xenetic Bioscience, SAGE Therapeutics, Blueprint Medicines, Harmony Biosciences, and Seagen are some of the 84 competitors of AB Science.

  • What is AB Science’s annual earnings per share (EPS)?

    AB Science’s EPS for 12 months was -$0.22.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »